Title:
SMALL CELL LUNG CANCER THERAPEUTIC AGENT CONTAINING OLIGONUCLEOTIDE
Document Type and Number:
WIPO Patent Application WO/2020/027227
Kind Code:
A1
Abstract:
Disclosed is an oligonucleotide, or a pharmacologically acceptable salt thereof, that contains at least one prescribed nucleoside structure, is capable of binding with a human nSR100 gene, and has activity to suppress the expression of the human nSR100 gene. The length of this oligonucleotide is 12-20 bases, and the oligonucleotide is complementary to a prescribed target region. Also disclosed is an nSR100-gene-expression-suppressing agent and a cancer therapeutic agent that contain the oligonucleotide or a pharmacologically acceptable salt thereof. This cancer therapeutic agent can be used in the treatment of small cell lung cancer, prostate cancer, or breast cancer.
Inventors:
SHIMOJO MASAHITO (JP)
OBIKA SATOSHI (JP)
KASAHARA YUYA (JP)
SUZUKI TAKAO (JP)
YAMAGAMI MASAKI (JP)
UMEMOTO TADASHI (JP)
OBIKA SATOSHI (JP)
KASAHARA YUYA (JP)
SUZUKI TAKAO (JP)
YAMAGAMI MASAKI (JP)
UMEMOTO TADASHI (JP)
Application Number:
PCT/JP2019/030090
Publication Date:
February 06, 2020
Filing Date:
July 31, 2019
Export Citation:
Assignee:
UNIV OSAKA (JP)
NAT INST BIOMEDICAL INNOVATION HEALTH & NUTRITION (JP)
NAT INST BIOMEDICAL INNOVATION HEALTH & NUTRITION (JP)
International Classes:
C07H21/04; A61K31/7125; A61K48/00; A61P11/00; A61P13/08; A61P15/00; A61P35/00; A61P43/00; C12N15/113
Domestic Patent References:
| WO2015012175A1 | 2015-01-29 | |||
| WO2017053722A1 | 2017-03-30 | |||
| WO2011052436A1 | 2011-05-05 | |||
| WO2014046212A1 | 2014-03-27 | |||
| WO2015125783A1 | 2015-08-27 | |||
| WO2015012175A1 | 2015-01-29 | |||
| WO2011052436A1 | 2011-05-05 | |||
| WO2014046212A1 | 2014-03-27 | |||
| WO2015125783A1 | 2015-08-27 |
Foreign References:
| JP2007536925A | 2007-12-20 | |||
| JP2008500039A | 2008-01-10 | |||
| US20050244851A1 | 2005-11-03 | |||
| US20050272080A1 | 2005-12-08 | |||
| JP2014043462A | 2014-03-13 |
Other References:
SHIMOJO, M. ET AL.: "The Small Cell Lung Cancer-Specific Isoform of REl-Silencing Transcription Factor (REST) Is Regulated By Neural-Specific Ser/Arg Repeat-Related Protein of 100 kDa (nSR100", MOLECULAR CANCER RESEARCH, vol. 11, no. 10, 2013, pages 1258 - 1268, XP055682058
SHIMOJO, M. ET AL.: "A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer", SCIENTIFIC REPORTS, vol. 9, 20 May 2019 (2019-05-20), pages 7618, XP055682060, Retrieved from the Internet
MOL. CANCER RES., vol. 11, no. 10, 2013, pages 1258 - 1268
"GenBank", Database accession no. NM_194286.3
M. KUWAHARA ET AL., NUCLEIC ACIDS RES., vol. 36, no. 13, 2008, pages 4257 - 65
TETRAHEDRON LETTERS, vol. 22, 1981, pages 1859 - 1862
NUCLEIC ACIDS RESEARCH, vol. 43, 2015, pages e128
See also references of EP 3831837A4
SHIMOJO, M. ET AL.: "A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer", SCIENTIFIC REPORTS, vol. 9, 20 May 2019 (2019-05-20), pages 7618, XP055682060, Retrieved from the Internet
MOL. CANCER RES., vol. 11, no. 10, 2013, pages 1258 - 1268
"GenBank", Database accession no. NM_194286.3
M. KUWAHARA ET AL., NUCLEIC ACIDS RES., vol. 36, no. 13, 2008, pages 4257 - 65
TETRAHEDRON LETTERS, vol. 22, 1981, pages 1859 - 1862
NUCLEIC ACIDS RESEARCH, vol. 43, 2015, pages e128
See also references of EP 3831837A4
Attorney, Agent or Firm:
NAKAMICHI, Yoshihiro et al. (JP)
Download PDF: